A study of p53 expression in transitional cell carcinoma of urinary bladder in Erbil governorate

Salah A. Ali; Bakir Sadeq ------

doi:10.15218/zjms.2012.0042

Authors

Salah A. Ali Department of Pathology, College of Medicine, Hawler Medical University, Erbil, Iraq.
Bakir Sadeq ------ Maternity hospital, Erbil, Iraq.

DOI:

https://doi.org/10.15218/zjms.2012.0042

Keywords:

Urothelial carcinoma of urinary bladder, P53

Abstract

Background and objectives: This study aimed to evaluate p53 protein expression in both normal bladder epithelium and in cases of transitional cell carcinoma (TCC) of urinary bladder by immunohistochemical study and to correlate p53 expression in urothelial cancer with other clinico-pathological parameters. Methods:This is a retrospective and prospective study for sample collection during the period from January 2006-May 2009. The samples studied included 105 formalin fixed, paraffin embedded urinary bladder tissue specimens; they consisted of the following diagnostic categories: chronic non specific cystitis (n=5) and urothelial cancer (n=100). In this study the nuclear p53 protein expression was detected in tissue samples by Dako Cytomation. LSAB + System-HRP staining protocol using monoclonal mouse anti human protein DO-7. Results:None of the chronic non specific cystitis cases showed p53 nuclear immunostaining, while 93% of urothelial cancer specimens examined showed immunopositivity for p53 protein. In this study, a statistically significant correlation was observed between p53 overexpression rate with the tumor grade (p= <0.001) and histological architecture (p= 0.023), but not with other clinico-pathological parameters like age and gender. Conclusion: Results of the present study showed the validity and simplicity of application of immunohistochemistry in determining the status of p53 protein expression. The results suggest that p53 overexpression is strongly associated with the aggressiveness of urothelial cancer.

Metrics

Metrics Loading ...

References

Ploeg M, Aben K, and Kiemeney L The present and future burden of urinary bladder cancer in the world. World J Urol; (2009); 27:289-293.

Nieder A, Mackinnon J, Fleming L, Kearney J, Hu J, Sherman R et al Bladder cluster in Florida: Identifying population at risk. The Journal of Urology; (2009); 182:46-51.

Results of Iraqi Cancer Registry Iraqi Cancer Board: Baghdad, Iraq 2001.

Luis N, Knowles-L E, Real F Molecular biology of bladder cancer. Clin Transl Oncol; (2007). ;9:5-12.

Pasin E, Josephson D, Mitra A, Cote R, and Stein J Superficial bladder cancer: An update on etiology, molecular development, classification, and natural history. Rev Urol; (2008). ;10(1):31-43.

Fernando SE, Wu X, Peersa LS P53 over expression receptor and steroid hormone status in endometrial carcinoma. Int J Surg Pathol; (2000); 8:213-222.

Etebary M, Jahanazad I, Mohagheghi MA, Azizi E Immunohistochemical analysis of p53 and its correlation to the other prognostic factors in breast cancers. Acta Medica Iranica; (2002); 40(2): 88-94.

Schlemper RJ, Riddel RH, Kato Y, Borchard F, Cooper H S, Dawsey SM et al The Vienna Classification gastrointestinal epithelial neoplasia; GUT (2000); 47: 251-255.

Kamaran A and Pirim I Predictor of Progression in Gastric Carcinoma. The Internet Journal of Genomics and Proteomics; 3(1): (2007); 1540-2630.

Bai L and Zhu WG p53: Structure, Function and Therputic Applications; (2006); 2(4):141-153.

Martine Ploeg, Katija K. H. Aben, Lambertus A. Kiemeney The present and future burden of urinary bladder cancer in the world. World J Urol; (2009); 27:289-293.

Al-Azzawi SN. Depleted uranium radioactive contamination in Iraq: an overview. Global Research. Vol 1. August 2006:4.20-25

George B, Datar R, Wu L, Cai J, Patten N, Beil S et al P53 gene and protein status: The role of p53 alteration in predicting outcome in patients with bladder cancer. J Clin Oncol; (2007); 25: 5352-5358.

Ersig D, Spruck C, Nichols P, Chaiwun B, Steven K, Groshen N et al p53 nuclear protein accumulation correlates with mutations in the p53 gene, tumor grade, and stage in bladder cancer. American Journal of Pathology; (1993); 143:1389-1397.

Lu M, Wikman T, Orntoft T, Charytonowicz E, Rabbani F, Zhang et al Impact of alteration affecting the p53 pathway in bladder cancer of clinical outcome, assessed by conventional and Array-based methods. Clinical Cancer Research; (2002) 8: 171-179.

Ersig D, Elmajian D, Groshen S, Freeman J, Stein J, Chen S et al Accumulatiion of nuclear p53 and tumor progression in bladder cancer. The NEW ENGLAND JOURNAL of MEDICINE; (1994); 331:1259-1264.

Sarkis A, Dalbagni G, Cordon-Cardo C, Zhang Z, Shienfeld J, Fair W et al Nuclear over expression of p53 protein in transitional cell bladder carcinoma: A marker for disease progression. J Natl Cancer Ins; (1993). 85:53-59

Malats N, Bustos A, Nascimento C, Fernandez F, Rivas M, Puente D et al P53 as prognostic marker for bladder cancer. Lancet Oncol; (2005).6: 678-686.

Emrbağci A, Yağci F, Sarica K, Karkök M, and Erturhan S (2002). Predictive value of p53 and NAT2 enzyme for disease free survival in patients with superficial bladder cancer. Turkish Journal of Cancer; vol 32/ no. 3.

Matalka I, Bani-Hani K, Shotar A, Bani Hani O, and Bani-Hani I Transitional cell carcinoma of the urinary bladder: a clinicopathological study. Singapore Med J; (2008). 49 (10): 790.

Cheng L, Neumann R, Nehra A, Spotts B, Weaver A, and Bostwick D Cancer heterogeneity and its biologic implications in the grading of urothelial carcinoma. American Cancer Society; (2000). 88:1663-1670.

Boudreaux K, Clark P, Lowrance W, Rumohr J, Barocas D, Cooksoon M et al Comparrision of American Joint Committee on Cancer Pathological Stage T2a Versus T2b Urothelial Carcinoma:Analysis of Patient Outcomes in Organ Confined Bladder Cancer. The Journal of Urology; (2009). 181(2):540-546.

Oh B, Sim J, Park CH, Ruy S, and Park Y Prognostic value of expression of mutant p53 and EGFR in transitional cell carcinoma of the bladder. J Korean Cancer assoc; (1997). 29: 663-672.

Kwak D, Ha J, Chang H, Choi M, Park Ch, and Kim Ch Clinical implications of the expression of Survivin and p53 in superficial transitional cell carcinoma of the bladder, Korean J Urol; (2009). 50: 12-17.

Sinik Z, Alkibay T, Ataoglu Ö, Biri H, Sözen S, Deniz N et al (Nuclear p53 overexpression in bladder, prostate, and renal carcinomas. Int J Urol; 1997).:546-551.

Halimi M, Salehi A, Baybordi H, and Nezami N Immunohistochemical positive stained p53 protein in bladder transitional cell carcinoma. Indian Journal of Pathology and Microbiology; (2009). 52(2).

Hemal A, Khaitan A, Dinda A, Gupta P, Seth A, Dogra P et al Prognostic significance of p53 nuclear overexpression in patients of muscle invasive urinary bladder carcinoma treated with cystectomy. Urol Int ; (2003). 70: 42-46.

Lipponen PK Overexpression of p53 nuclear oncoprotein in transitional cell bladder cancer and its prognostic value. Int J Cancer ; (1993). 53: 365-370.